China Resources Pharmaceutical Commercial Group International Trade Co., Ltd.

China Resources Pharmaceutical Commercial Group International Trade Co., Ltd. (abbreviated as "Runyao International Trade") is a subsidiary of China Resources Pharmaceutical Commercial Group Co., Ltd. Runyao International Trade was registered in 1999 with a registered capital of RMB 80 million. It is a large comprehensive pharmaceutical enterprise integrating pharmaceutical import trade, pharmaceutical market promotion, domestic hospital drug supply, cross-regional commercial distribution, and sales of medical devices and consumables. The company's headquarters is located at Building 9, Zone 2, Hanwei International Plaza, Fengtai District, Beijing, in the Fengtai Park of Zhongguancun National Independent Innovation Demonstration Zone. The company has a wholly-owned subsidiary—China Resources Guokang (Guangdong) Pharmaceutical Co., Ltd. It currently has more than 200 employees. China Resources Pharmaceutical Commercial Group International Trade Co., Ltd. has become a well-known pharmaceutical enterprise, and has been awarded multiple honors for consecutive years, including National Top 100 Pharmaceutical Commercial Sales Enterprises, Outstanding Contribution Enterprise of Fengtai District, and Excellent Taxpaying Enterprise. Its business has grown over more than ten years. With Beijing, Shanghai, and Guangzhou as radiation centers, its sales network covers major cities across the country. Direct sales customers include more than 600 large hospitals and more than 360 commercial companies. Runyao International Trade has become a brand trusted by people. Leaders of the Beijing Municipal Government, the Ministry of Health, and the General Logistics Department have visited China Resources Guokang many times, giving attention and support. Runyao International Trade is mainly engaged in agency distribution of new and special drugs in the China region, as well as agency distribution and delivery of bid-winning products for the entire military coordination, General Logistics Department bidding, and tenders in Beijing, Shanghai, Guangdong, and other cities. This is also the foundation and source of Runyao International Trade's entrepreneurial development and the main force of its development. Runyao International Trade has consistently adhered to the service philosophy of "Creating value for customers is the embodiment of Runyao International Trade's value! Winning customers' praise is the success of Runyao International Trade's service!" and has established a sales philosophy with new and special drugs in fields such as anti-tumor, transplantation and immunity, and central nervous system as its main professional areas. After years of development, Runyao International Trade has established strategic partnerships with many well-known enterprises, achieving win-win results with manufacturers. Runyao International Trade attaches importance to informationization construction and is committed to building a domestic pharmaceutical commercial trading platform, providing a data transmission platform for suppliers and customers. Suppliers can view their product information and adjust and replenish goods based on the information. Our customers can select varieties to purchase, purchase online, and connect with their own data. Runyao International Trade focuses on many diseases that seriously affect human health and endanger life, such as tumors, blood diseases, and organ transplantation. It introduces foreign *cutting-edge* and *advanced* treatment concepts, plans, and products, bringing hope to patients across the country; we provide one-stop services for manufacturers, from drug registration, drug inspection, import, customs declaration, bidding, pricing, and promotion to agency sales, helping manufacturers integrate into the pharmaceutical value chain with first-class strategic alliance partners. Core products: anti-tumor drugs; transplantation and nephrology drugs; psychiatric drugs; globally blockbuster patented drugs; patented products of foreign small and medium-sized pharmaceutical enterprises with therapeutic characteristics that have not yet entered China.